Shift Bioscience is developing biological-age control to end the diseases of aging, promising a future where you can routinely reset to prime-of-life. Driven by the increasing toll of chronic diseases of ageing, US healthcare spending is predicted to rise from 18% to 34% of GDP by 2040. The collision of Cov19 with chronic diseases will only worsen this crisis. Therapeutics targeting the causes of ageing rather than the symptoms are urgently needed and offer the only sustainable-solution. Pluripotent ‘Yamanaka factors’ have comprehensive rejuvenative properties but can induce cancer, raising concerns about therapeutic translation. Shift Bioscience is focused on discovery of safer biology for biological age control through a machine learning approach. This promises a future where you can routinely reset to prime-of-life and step back from the precipice of age-linked diseases.